12 stories
The FLOW trial showed semaglutide reduced major kidney events by 24%, and retatrutide demonstrated up to 28.7% weight loss in TRIUMPH-4. The full pipeline including CagriSema, MariTide, and survodutide was presented.
Retatrutide met its primary endpoint of superior A1C reduction and all key secondary endpoints at 40 weeks compared with placebo in type 2 diabetes patients, also demonstrating significant weight loss.
TikTok users on retatrutide report emotional blunting. Neuroscientist Paul Kenny of Mount Sinai says researchers are investigating whether GLP-1 drugs act as general reward dampeners affecting the brain's mesolimbic system.
Deep dive into the retatrutide hype cycle triggered by Andrew Huberman's endorsement and looksmaxxing influencers. Frames the triple-agonist as potentially more consequential than Ozempic.
Psychiatric Times provides educational review of the incretin system covering the shift toward oral nonpeptide small-molecule GLP-1 RAs and triple agonists expected within 1-2 years.
Eli Lilly's triple agonist (GIP/GLP-1/glucagon) retatrutide met its primary A1C reduction endpoint and all key secondary endpoints at 40 weeks in the TRANSCEND-T2D-1 trial.
Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist retatrutide demonstrated up to 28.7% weight loss along with significant knee pain reductions in obesity patients with osteoarthritis. Seven additional Phase 3 trials expected to report throughout 2026.
Analyst deep-dive into Lilly's position as healthcare's most valuable company, with ~60% U.S. incretin market share driven by tirzepatide and a retatrutide pipeline showing ~30% weight loss potential.
Findings presented at The Liver Meeting show retatrutide cleared fatty liver disease in more than 85% of patients with obesity, dramatically expanding its therapeutic profile beyond weight loss.
Detailed Phase 3 results for Eli Lilly's triple-agonist (GLP-1/GIP/glucagon) showed significant weight loss alongside improved pain and physical function in obesity-related knee osteoarthritis. Seven additional Phase 3 trials underway.
Eli Lilly's triple-agonist achieved record weight loss at the highest dose with substantial reductions in knee osteoarthritis pain. Seven more Phase 3 trials expected in 2026.
Analysis of the TRIUMPH program (TRIUMPH-1 through TRIUMPH-4) published in Diabetes, Obesity, and Metabolism shows unprecedented average weight reduction of up to 24% across 5,800+ adults.